Sacituzumab govitecan for advanced cancers with moderate liver issues
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid cancer that has been confirmed by a tissue biopsy and is measurable or can’t be measured by scans but is still tracked.
- Your overall health/activity is good enough (ECOG score 0–2, meaning you can still do self-care and some daily activities).
- Your blood counts are high enough before starting (hemoglobin ≥9, neutrophils ≥1,500, platelets ≥100,000) without needing blood transfusions or growth-factor shots right beforehand.
- Your kidneys are working well enough (creatinine clearance ≥30 mL/min).
- You have either normal liver tests or moderate liver impairment (bilirubin in a moderate range, with AST at any level), and you can consent appropriately if you have had liver-related confusion (encephalopathy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
This trial tests a new drug called sacituzumab govitecan for people with advanced thyroid cancer that has stopped responding to standard treatments. It may be an option for those with differentiated thyroid cancer (after certain prior therapies) or anaplastic thyroid cancer (first-line or after one prior treatment).
Hear when a new Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.